Related Experiment Videos
Serum ganglioside patterns in multiple sclerosis.
E Zaprianova1, D Deleva, P Ilinov
1Institute of Experimental Morphology and Anthropology. Bulgarian Academy of Sciences, Sofia.
Neurochemical Research
|August 2, 2001
Summary
Multiple sclerosis (MS) patients show altered ganglioside levels in serum. Early MS attacks reveal increased GM1 and GD1a, suggesting demyelination and neuron injury in this autoimmune disease.
Area of Science:
- Neuroscience
- Biochemistry
- Immunology
Background:
- Multiple Sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
- Gangliosides are complex glycosphingolipids found in cell membranes, particularly abundant in neurons and myelin.
- Alterations in ganglioside profiles have been implicated in various neurological disorders.
Purpose of the Study:
- To investigate the relative distribution of serum gangliosides in patients with multiple sclerosis (MS).
- To correlate specific ganglioside changes with disease activity and duration in relapsing-remitting MS (RRMS).
Main Methods:
- Serum samples were collected from 37 MS patients and 30 healthy controls.
- Quantitative analysis of ganglioside composition (GM1, GD1a, GM3) was performed.
Main Results:
- RRMS patients during their first attack showed increased serum GM1 and GD1a, and decreased GM3.
- Long-standing RRMS patients in relapse exhibited decreased GM1 and increased GD1a.
- Elevated GD1a suggests potential neuron injury in early and chronic RRMS.
- Increased GM1 during the first attack supports ganglioside involvement in early MS demyelination.
Conclusions:
- Serum ganglioside profiles are altered in multiple sclerosis patients.
- Specific ganglioside changes correlate with disease status, indicating potential roles in MS pathogenesis.
- Gangliosides may serve as biomarkers for early demyelination and neuron injury in MS.